Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCF, FRANKFURT: HBP0), a clinical-stage oncology company developing therapies for difficult-to-treat cancers, announced on September 28, 2026, the appointment of Karen Krumeich, Jamieson Bondarenko, Charmaine Lykins, and Dirk Brockstedt to its Board of Directors. Ms. Krumeich has also been appointed Chair of the Board and Audit Committee. The company simultaneously announced the voluntary resignations of Jacek Antas, Malgorzata Laube, and Jerzy Leszczynski. The changes are part of an ongoing board renewal, aiming to bring complementary expertise in biotechnology leadership, corporate governance, finance, scientific and clinical development, commercialization, and capital markets.
This board overhaul matters because it signals a strategic push to strengthen governance and expertise as Helix advances its oncology pipeline. The new directors bring a wealth of experience: Karen Krumeich is a life sciences financial executive with CFO experience at public and private companies, including Kazia Therapeutics and Soligenix; Jamieson Bondarenko is a capital markets expert and Chairman of BriaCell Therapeutics; Charmaine Lykins is a seasoned biopharmaceutical commercial leader with over 30 years of experience, including roles at Karuna Therapeutics and Acadia Pharmaceuticals; and Dirk Brockstedt is a biotechnology executive and scientist with over 25 years in research and clinical development, having served as CSO of RAPT Therapeutics. Their collective expertise is expected to guide Helix through its next phase of growth.
CEO Thomas Mehrling commented, “We are very pleased to welcome Karen, Jamieson, Charmaine and Dirk to Helix’s Board. Together, these Board members bring an exceptional breadth of complementary expertise… Their collective experience significantly strengthens our Board at an important stage in Helix’s evolution.” He also thanked the departing directors for their service. The reconstituted board now comprises six directors, four of whom are independent, and the Audit Committee is entirely independent, chaired by Ms. Krumeich.
Helix BioPharma focuses on developing therapies for underserved patient populations with difficult-to-treat cancers. Its pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate for non-small cell lung cancer, and includes pre-IND candidates LEUMUNA™ for post-transplant leukemia relapse and GEMCEDA™ for advanced solid tumors. The board changes are intended to support the company’s strategic objectives and long-term value creation. For more information, visit https://www.helixbiopharma.com/. The original release can be viewed on www.newmediawire.com.
